CVE-2008-3371

Public Exploit

Description

Directory traversal vulnerability in install/help.php in TalkBack 2.3.5, and other versions before 2.3.6.2, allows remote attackers to include and execute arbitrary local files via directory traversal sequences in the language parameter.

Category

7.5
CVSS
Severity: High
CVSS 2.0 •
EPSS 6.80% Top 10%
Third-Party Advisory securityreason.com
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
https://www.exploit-db.com/exploits/6451 exploit
http://www.vupen.com/english/advisories/2008/2211/references vdb entry
https://www.exploit-db.com/exploits/9095 exploit
https://exchange.xforce.ibmcloud.com/vulnerabilities/44018 vdb entry
http://www.packetstormsecurity.org/0907-exploits/talkback-lfiexec.txt
http://securityreason.com/securityalert/4067 third party advisory
https://www.exploit-db.com/exploits/6148 exploit
http://www.securityfocus.com/bid/30393 vdb entry exploit
http://www.scripts.oldguy.us/talkback/release-notes.html

Frequently Asked Questions

What is the severity of CVE-2008-3371?
CVE-2008-3371 has been scored as a high severity vulnerability.
How to fix CVE-2008-3371?
To fix CVE-2008-3371, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2008-3371 being actively exploited in the wild?
It is possible that CVE-2008-3371 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~7% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.